Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231462 | 0.81 | TNF (0.49) | LDHAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6233530 | 0.80 | ALDH1A1 (0.47) | KMT2AL3MBTL1CYP2C19ALDH1A1POLB | |
| SCHEMBL6236231 | 0.79 | GAA (0.61) | ALDH1A1 | |
| SCHEMBL6484578 | 0.77 | FFAR1 (0.66) | FFAR1KMT2AATML3MBTL1LDHA | |
| SCHEMBL10962386 | 0.76 | FFAR1 (0.44) | FFAR1KMT2AATML3MBTL1LDHA | |
| SCHEMBL6231164 | 0.76 | POLB (0.51) | KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6235254 | 0.76 | PTGES (0.49) | KMT2ACYP2C19ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6571679 | 0.76 | CYP2C19 (0.74) | FFAR1L3MBTL1LDHACYP2C19ALDH1A1 | |
| SCHEMBL7891728 | 0.76 | L3MBTL1 (0.68) | FFAR1KMT2AATML3MBTL1LDHA | |
| SCHEMBL2226074 | 0.75 | L3MBTL1 (0.68) | FFAR1KMT2AATML3MBTL1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282397-B1 | USE OF COMPOUNDS CONTAINING A THIO-ETHER, SULPHOXIDE OR SULPHONE FUNCTION AS COSMETIC ANTI-POLLUTION AGENT | OREAL (FR) | 2005-05-04 | — | — | EP | claimed |
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | claimed |
| EP-0858319-B1 | USE OF CARBOXYLIC ACIDS HAVING A SULPHUR FUNCTION FOR PROMOTING SKIN EXFOLIATION OR STIMULATING EPIDERMAL REGENERATION | OREAL (FR) | 2003-07-23 | — | — | EP | claimed |
| US-6153649-A | Use of carboxylic acids having a sulphur function for promoting skin exfoliation or stimulating epidermal regeneration | L'OREAL (FR) | 2000-11-28 | — | — | US | claimed |
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | disclosed |
| US-6153649-A | Use of carboxylic acids having a sulphur function for promoting skin exfoliation or stimulating epidermal regeneration | L'OREAL (FR) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | TST, STS, MPST | FFAR1 2920/4885KMT2A 3028/4885ATM 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.